Does the urinary excretion of α1-microglobulin and albumin predict clinical disease activity in ulcerative colitis?

Advances in Therapy

Volumn 25, Issue 12, 2008, Pages 1342-1352

  Derici, Ulver ^a   Tuncer, Candan ^b   Ebinç, Fatma Ayerden ^a   Mutluay, Ruya ^a   Yakaryilmaz, Fahri ^b   Kulaksizoglu, Sevsen ^c   Soylemezoglu, Oguz ^d   Sindel, Sukru ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Gastroenterology Department   (Turkey)

^c Biochemistry Department   (Turkey)

^d Pediatric Nephrology Department   (Turkey)

Author keywords

Alfa 1 microglobulin; Inflammatory bowel disease; Microalbuminuria

Indexed keywords

ALPHA GLOBULIN; ALPHA-1-MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ALBUMINURIA; BLOOD; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; ULCERATIVE COLITIS; URINE;

ADULT; ALBUMINURIA; ALPHA-GLOBULINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE;

EID: 73349109143     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0109-8     Document Type: Article

References (42)

1. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patients with infammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:215-219.
2. Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in infammatory bowel disease? Am J Gastroenterol. 2001;96:2177-2183. (Pubitemid 32660915)
3. Rizzello F, Gionchetti P, Venturi A, Amadini C, Romagnoli R, Campieri M. Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ter. 2002;16(suppl. 4):3-6. (Pubitemid 34595610)
4. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of infammatory bowel disease. Am J Gastroenterol. 2000;95:359-367. (Pubitemid 30106162)
5. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric infammatory bowel disease. Gastroenterology. 1998;115:822-829. (Pubitemid 28452928)
6. Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N. Soluble adhesion molecules in infammatory bowel disease. Ir J Med Sci. 2001;170:107-111. (Pubitemid 32701020)
7. Patel RT, Pall AA, Adu D, Keighley MR. Circulating soluble adhesion molecules in infammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:1037-1041. (Pubitemid 26014458)
8. Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in infammatory bowel disease: relation to circulating interleukin-6. Gut. 1995;36:45-49.
9. Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig Dis Sci. 1998;43:2071-2079.
10. Prior C, Bollbach R, Fuchs D, et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta. 1986;155:11-21. (Pubitemid 16035025)
11. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal infammation. Lancet. 1992;339:89-91.
12. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efcacy of treatment of infammatory bowel disease. Gut. 1995;37:260-263.
13. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in infammatory bowel disease. Gut. 1995;36:724-730.
14. Herrlinger KR, Nofz MK, Fellermann K, Schmidt K, Steinhof J, Stange EF. Minimal renal dysfunction in infammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ter. 2001;15:363-369. (Pubitemid 32187558)
15. Mahmud N, McDonald GS, Kelleher D, Weir DG. Microalbuminuria correlates with intestinal histopathological grading in patients with infammatory bowel disease. Gut. 1996;38:99-103. (Pubitemid 26020935)
16. Mahmud N, Stinson J, O'Connell MA, et al. Microalbuminuria in infammatory bowel disease. Gut. 1994;35:1599-1604.
17. Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute infammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ter. 2001;15:1131-1137. (Pubitemid 32675446)
18. Schreiber S, Hämling J, Zehnter E, et al. Renal tubular dysfunction in patients with infammatory bowel disease treated with aminosalicylate. Gut. 1997;40:761-766. (Pubitemid 27305469)
19. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86. (Pubitemid 19032930)
20. Narayanan S, Appleton HD. Creatinine: a review. Clin Chem. 1990;26:1119-1126.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am J Kidney Dis. 2002:39(suppl. 1):S46-S76.
22. Whicher JT, Price CP, Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. Crit Rev Clin Lab Sci. 1983;18:213-260.
23. Pontremoli R, Sofa A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension. 1997;30:1135-1143. (Pubitemid 27476170)
24. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic signifcance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 1992;41:836-839.
25. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418. (Pubitemid 27300386)
26. Niederstadt C, Happ T, Tatsis E, Schnabel A, Steinhof J. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:28-33. (Pubitemid 29509653)
27. Dawnay A, Wilson AG, Lamb E, Kirby JD, Cattell WR. Microalbuminuria in systemic sclerosis. Ann Rheum Dis. 1992;51:384-388.
28. Pedersen LM, Sorensen PG. Mediators of infammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma. Br J Haematol. 2003;121:275-279. (Pubitemid 36560594)
29. Itoh Y, Enomoto H, Takagi K, Kawai T, Yamanaka T. Human alpha 1-microglobulin in various hepatic disorders. Digestion. 1983;27:75-80. (Pubitemid 13041630)
30. Falkenberg C, Blom A, Fries E, et al. Alpha1-microglobulin and bikunin in rats with collagen II-induced arthritis: plasma levels and liver mRNA content. Scand J Immunol. 1997;46:122-128. (Pubitemid 27323839)
31. Svensson L, Ravnskov U. Alpha1-microglobulin, a new low molecular weight plasma protein. Clin Chim Acta. 1976;73:415-422.
32. Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta. 2004;346:107-118. (Pubitemid 38901041)
33. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003;26:338-342. (Pubitemid 36929052)
34. Moriguchi J, Ezaki T, Tsukahara T, et al. Alpha1-microglobulin as a promising marker of cadmium-induced tubular dysfunction, possibly better than beta2-microglobulin. Toxicol Lett. 2004;148:11-20. (Pubitemid 38264518)
35. Yu H, Yanagisawa Y, Forbes MA, Cooper EH, Crockson RA, MacLennan IC. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol. 1983;36:253-259. (Pubitemid 13160686)
36. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433-438.
37. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol. 1992;140:659-663.
38. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal infammation. Lancet. 1993;341:711-714. (Pubitemid 23085176)
39. Mayer L, Janowitz H. Extraintestinal manifestations of infammatory bowel disease. In: Kirsner, JB, Shorter RG, eds. Infammatory Bowel Disease. Philadelphia: Lea & Febinger; 1988:299-317.
40. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ter. 2002;16:207-215. (Pubitemid 34146361)
41. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: Effects of drug treatment. Gut. 1992;33:1348-1352.
42. Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic infammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8:461-468. (Pubitemid 26181683)